Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections
- 1.7k Downloads
Vancomycin is commonly used to treat staphylococcal infections, but there has not been a definitive analysis of the pharmacokinetics of this antibacterial in relation to minimum inhibitory concentration (MIC) that could be used to determine a target pharmacodynamic index for treatment optimisation.
To clarify relationships between vancomycin dosage, serum concentration, MIC and antimicrobial activity by using data gathered from a therapeutic monitoring environment that observes failures in some cases.
We investigated all patients with a Staphylococcus aureus lower respiratory tract infection at a 300-bed teaching hospital in the US during a 1-year period. Clinical and pharmacokinetic information was used to determine the following: (i) whether steady-state 24-hour area under the concentration-time curve (AUC24) divided by the MIC (AUC24/MIC) values for vancomycin could be precisely calculated with a software program; (ii) whether the percentage of time vancomycin serum concentrations were above the MIC (%Time>MIC) was an important determinant of vancomycin response; (iii) whether the time to bacterial eradication differed as the AUC24/MIC value increased; (iv) whether the time to bacterial eradication for vancomycin differed compared with other antibacterials at the same AUC24/MIC value; and (v) whether a relationship existed between time to bacterial eradication and time to significant clinical improvement of pneumonia symptoms.
The median age of the 108 patients studied was 74 (range 32–93) years. Measured vancomycin AUC24/MIC values were precisely predicted with the A.U.I.C. calculator in a subset of our patients (r2 = 0.935). Clinical and bacteriological response to vancomycin therapy was superior in patients with higher (≥400) AUC24/MIC values (p = 0.0046), but no relationship was identified between vancomycin %Time>MIC and infection response. Bacterial eradication of S. aureus (both methicillin-susceptible and methicillin-resistant) occurred more rapidly (p = 0.0402) with vancomycin when a threshold AUC24/MIC value was reached. S. aureus killing rates were slower with vancomycin than with other antistaphylococcal antibacterials (p = 0.002). There was a significant relationship (p < 0.0001) between time to bacterial eradication and the time to substantial improvement in pneumonia score.
Vancomycin AUC24/MIC values predict time-related clinical and bacteriological outcomes for patients with lower respiratory tract infections caused by methicillin-resistant S. aureus.
KeywordsMinimum Inhibitory Concentration Vancomycin Lower Respiratory Tract Infection Bacterial Eradication Vancomycin Dosage
No financial support was obtained for the preparation of this article. The authors have no conflicts of interest directly relevant to the content of this study.
- 27.Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristindalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46(5): 775–84PubMedCrossRefGoogle Scholar
- 33.Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44(2): 263–73PubMedCrossRefGoogle Scholar
- 35.ASHP. Correction on AUIC and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections caused by Staphylococcus aureus. Am J Health Syst Pharm 2001; 58: 78Google Scholar
- 36.Center for Drug Evaluation and Research. Evaluating clinical studies of antimicrobials in the division of anti-infective drug products. FDA draft guidance [online]. Available from URL: http://www.fda.gov/cder/guidance/draft9al.pdf [Accessed 2004 Aug 9]
- 38.Luzier A, Goss TF, Cumbo TJ, et al. Mathematical examination of dual individualization principles (III): development of a scoring system for pneumonia staging and quantitation of response to antibiotics: results in cefmenoxime-treated patients. Ann Pharmacother 1992; 26(11): 1358–65PubMedGoogle Scholar
- 55.Houlihan HH, Mercier RC, Rybak MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997; 41(11): 2497–501PubMedGoogle Scholar
- 59.Klepser ME, Kang SL, McGrath BJ. Influence of vancomycin serum concentration on the outcome of gram-positive infections [abstract]. Program and abstracts of the American College of Clinical Pharmacy Annual Winter Meeting; 1994 Feb 6–9; San DiegoGoogle Scholar
- 60.Garrod LP, Lambert HP, O’Grady F. Various antibacterial agents. 4th ed. London: Churchill Livingstone, 1973Google Scholar
- 67.Matzke GR. Vancomycin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics, principles of drug monitoring. Vancouver (WA): Applied Therapeutics Inc., 1992: 15.1–15.30Google Scholar
- 72.Moise PA, Forrest A, Birmingham MC, et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50(6): 1017–26PubMedCrossRefGoogle Scholar